Evidence map›Paper›PMID 23981510›Full record

ArticleJournal of neurodevelopmental disorders2013

Aberrant basal ganglia metabolism in fragile X syndrome: a magnetic resonance spectroscopy study.

Jennifer Lynn Bruno, Elizabeth Walter Shelly, Eve-Marie Quintin, Maryam Rostami, Sweta Patnaik, Daniel Spielman, Dirk Mayer, Meng Gu, Amy A Lightbody, Allan L Reiss

Open access · goldAbstract read
In one paragraph

Article in Journal of neurodevelopmental disorders, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Developmental studies in fragile X syndrome.Journal of neurodevelopmental disorders · 2020
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jennifer Lynn BrunoCenter for Interdisciplinary Brain Sciences Research, Stanford University, 401 Quarry Road, Stanford, CA 94305-5795, USA. areiss1@stanford.edu.
Elizabeth Walter Shelly
Eve-Marie Quintin
Maryam Rostami
Sweta Patnaik
Daniel Spielman
Dirk Mayer
Meng Gu
Amy A Lightbody
Allan L Reiss
Stanford University · US

Funding

TRAINING FOR CHILD PSYCHIATRY AND CHILD DEVELOPMENTT32MH019908 · NIMH · STANFORD UNIVERSITY · PI IAN H GOTLIB, DAVID S HONG · 1993 to 2026
$6.3M
NIMH NIH HHS T32 MH019908
6 · The paper itself

Abstract

backgroundThe profile of cognitive and behavioral variation observed in individuals with fragile X syndrome (FXS), the most common known cause of inherited intellectual impairment, suggests aberrant functioning of specific brain systems. Research investigating animal models of FXS, characterized by limited or lack of fragile X mental retardation protein, (FMRP), has linked brain dysfunction to deficits in the cholinergic and glutamatergic systems. Thus, we sought to examine in vivo levels of neurometabolites related to cholinergic and glutamatergic functioning in males and females with FXS.

methodsThe study participants included 18 adolescents and young adults with FXS, and a comparison group of 18 individuals without FXS matched for age, sex and general intellectual functioning. Proton magnetic resonance spectroscopy (MRS) was used to assess neurometabolite levels in the caudate nucleus, a region known to be greatly enlarged and involved in abnormal brain circuitry in individuals with FXS. A general linear model framework was used to compare group differences in metabolite concentration.

resultsWe observed a decrease in choline (P = 0.027) and in glutamate + glutamine (P = 0.032) in the caudate nucleus of individuals with FXS, relative to individuals in the comparison group.

conclusionsThis study provides evidence of metabolite differences in the caudate nucleus, a brain region of potential importance to our understanding of the neural deficits underlying FXS. These metabolic differences may be related to aberrant receptor signaling seen in animal models. Furthermore, identification of the specific neurometabolites involved in FXS dysfunction could provide critical biomarkers for the design and efficacy tracking of disease-specific pharmacological treatments.

Identifiers

PMID23981510
PMCPMC3766683
OpenAlexW2106738680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.